Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I):

##STR00001##

or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein D, W, Z, R.sup.1, R.sup.2 and R.sup.3 are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

A light-emitting device includes: a first electrode; a second electrode facing the first electrode; and an interlayer between the first electrode and the second electrode and including an emission layer, wherein the interlayer includes a heterocyclic compound of Formula 1:

A.sub.1B.sub.1].sub.n1  Formula 1

wherein, in Formula 1, the variables are defined herein.

A light-emitting device includes: a first electrode; a second electrode facing the first electrode; and an interlayer between the first electrode and the second electrode and including an emission layer, wherein the interlayer includes a heterocyclic compound of Formula 1:

A.sub.1B.sub.1].sub.n1  Formula 1

wherein, in Formula 1, the variables are defined herein.

Provided is the nitrogen-containing compound shown in Chemical formula 1, an organic electroluminescent device, and an electronic apparatus, relating to the technical field of organic materials. The nitrogen-containing compound can improve the performance of the organic electroluminescent device. ##STR00001##

Provided is the nitrogen-containing compound shown in Chemical formula 1, an organic electroluminescent device, and an electronic apparatus, relating to the technical field of organic materials. The nitrogen-containing compound can improve the performance of the organic electroluminescent device. ##STR00001##

Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

The present invention relates to a new compound that can inhibit an anoctamin 6 protein, a composition comprising the compound, a method for preparing the compound, and a method for using the compound or composition.

The present invention relates to a new compound that can inhibit an anoctamin 6 protein, a composition comprising the compound, a method for preparing the compound, and a method for using the compound or composition.

Provided herein are compounds, compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.